Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Sci Rep. 2024 Sep 11;14(1):21201. doi: 10.1038/s41598-024-72324-z.
Myocardial ischemia-reperfusion injury (MIRI) is a significant complication following reperfusion therapy after myocardial infarction. Mitochondrial oxidative stress is a critical factor in MIRI, and Sirtuin 3 (SIRT3), as a major mitochondrial deacetylase, plays a key protective role, with its activity potentially regulated by O-GlcNAcylation. This study used the H9C2 cell line to establish a simulated ischemia/reperfusion (SI/R) model, we utilized co-immunoprecipitated to validate the relationship between O-GlcNAc transferase (OGT) and SIRT3, demonstrated SIRT3 O-GlcNAcylation sites through LC-MS/MS, and performed site mutations using CRISPR/Cas9 technology. The results were validated using immunoblotting. SIRT3 and superoxide dismutase 2 (SOD2) activities were detected using a fluorometric assay, while mitochondrial reactive oxygen species (MROS) levels and cellular apoptosis were assessed using immunofluorescence. We have identified an interaction between SIRT3 and OGT, where SIRT3 undergoes dynamic O-GlcNAcylation at the S190 site, facilitating SIRT3 deacetylase activity. During SI/R, elevated levels of O-GlcNAcylation activate SOD2 by promoting SIRT3 enzyme activity, thereby inhibiting excessive MROS production. This significantly mitigates the occurrence of malignant autophagy in myocardial cells during reperfusion, promoting their survival. Conversely, blocking SIRT3 O-GlcNAcylation at the S190 site exacerbates SI/R injury. We demonstrate that O-GlcNAcylation is a crucial post-translational modification (PTM) of SIRT3 during SI/R, shedding light on a promising mechanism for future therapeutic approaches.
心肌缺血再灌注损伤(MIRI)是心肌梗死后再灌注治疗的一种严重并发症。线粒体氧化应激是 MIRI 的一个关键因素,而 Sirtuin 3(SIRT3)作为主要的线粒体去乙酰化酶,发挥着关键的保护作用,其活性可能受到 O-GlcNAcylation 的调节。本研究使用 H9C2 细胞系建立了模拟缺血/再灌注(SI/R)模型,我们利用共免疫沉淀验证了 O-GlcNAc 转移酶(OGT)和 SIRT3 之间的关系,通过 LC-MS/MS 鉴定了 SIRT3 的 O-GlcNAcylation 位点,并使用 CRISPR/Cas9 技术进行了位点突变。结果通过免疫印迹进行了验证。使用荧光法检测 SIRT3 和超氧化物歧化酶 2(SOD2)的活性,通过免疫荧光法检测线粒体活性氧(MROS)水平和细胞凋亡。我们发现 SIRT3 和 OGT 之间存在相互作用,SIRT3 在 S190 位点发生动态 O-GlcNAcylation,促进 SIRT3 去乙酰化酶活性。在 SI/R 期间,O-GlcNAcylation 水平升高通过促进 SIRT3 酶活性来激活 SOD2,从而抑制过量的 MROS 产生。这显著减轻了再灌注期间心肌细胞中恶性自噬的发生,促进了它们的存活。相反,在 S190 位点阻断 SIRT3 的 O-GlcNAcylation 会加重 SI/R 损伤。我们证明了 O-GlcNAcylation 是 SIRT3 在 SI/R 过程中的一个关键翻译后修饰(PTM),为未来的治疗方法提供了一个有前途的机制。